发表一篇学和医学成像类SCI论文
需要多少钱?
Abstract:
BACKGROUND:Soft tissue sarcomas (STS) have a high risk of relapse in spite of the use of (neo)adjuvant chemotherapy. In this context, looking for new prognostic biomarkers is an interesting field of research. Our aim is to analyze the prognostic impact of neutrophil-to-lymphocyte ratio (NLR) and other serum markers in patients with STS who received chemotherapy with curative intent. MATERIALS AND METHODS:This is a retrospective observational study. We included all patients with STS (primary tumor, local recurrence or resected metastatic disease) treated with high-dose ifosfamide and epirubicin with curative intent from January 2007 to December 2018. The pretreatment NLR and other serum markers were calculated, selecting the median as the cut-off value for the survival and multivariate analysis. RESULTS:Seventy-nine patients were included. Median NLR, platelet-to-lymphocyte ratio (PLR) and lymphocyte-to-monocyte ratio (LMR) were 2.83, 174.05 and 3.25, respectively. Median progression-free survival (PFS) was significantly longer in patients with low NLR [not reached (NR) vs 21, 92 months, P < 0.01]. No significant differences were found for PFS regarding PLR or LMR. For overall survival (OS), a significant survival advantage was also found for patients with low NLR (NR vs 65.45 months, P = 0.01), without differences for PLR or LMR. In multivariate analysis, NLR remains an independent prognostic factor for PFS. CONCLUSION:In our cohort, low NLR was significantly associated with a longer PFS and OS, and is consolidated as an independent prognostic factor.
展开更多
最新影响因子:3.34 | 期刊ISSN:1699-048X | CiteScore:5.16 |
出版周期:Monthly | 是否OA:YES | 出版年份:2005 |
自引率:2.20% | 研究方向:医学-肿瘤学 |
出版地区:SPAIN |
SCI期刊coverage:Science Citation Index Expanded(科学引文索引扩展)
专业编辑在线一对一答疑及时解决您的问题
Clinical and Translational Oncology is an international journal devoted to fostering interaction between experimental and clinical oncology. It covers all aspects of research on cancer, from the more basic discoveries dealing with both cell and molecular biology of tumour cells, to the most advanced clinical assays of conventional and new drugs. In addition, the journal has a strong commitment to facilitating the transfer of knowledge from the basic laboratory to the clinical practice, with the publication of educational series devoted to closing the gap between molecular and clinical oncologists. Molecular biology of tumours, identification of biomarkers for cancer diagnosis, prognosis or prediction of treatment response, identification of new targets for cancer therapy, as well as development of new technologies for research and treatment of cancer are the major themes covered by both the educational series and research articles. A broad spectrum of subjects, including the molecular and cellular bases of disease, aetiology, pathophysiology, pathology, epidemiology, clinical features, and the diagnosis, prognosis and treatment of cancer, will be considered for publication.
《临床与转化肿瘤学》是一本致力于促进实验肿瘤学与临床肿瘤学相互作用的国际期刊。它涵盖了癌症研究的所有方面,从涉及肿瘤细胞和分子生物学的更基本的发现,到最先进的传统和新药的临床检测。此外,该杂志致力于促进从基础实验室到临床实践的知识转移,出版了一系列致力于缩小分子肿瘤学家和临床肿瘤学家之间差距的教育系列。肿瘤分子生物学、癌症诊断生物标记物的识别、治疗反应的预后或预测、癌症治疗新靶点的识别以及癌症研究和治疗新技术的开发是教育系列和研究文章的主题。将考虑发表广泛的主题,包括疾病的分子和细胞基础、病因学、病理生理学、病理学、流行病学、临床特征以及癌症的诊断、预后和治疗。
大类(学科) | 小类(学科) | 学科排名 |
医学 |
ONCOLOGY (肿瘤学) 4区 |
156/223 |
年度总发文量 | 年度论文发表量 | 年度综述发表量 |
179 | 144 | 35 |
引文计数(2018)
文献(2015-2017)
8579次引用
1661篇文献
序号 | 类别 | 排名 | 百分位 |
1 |
大类(学科):Medicine
小类(学科):Pulmonary and Respiratory Medicine
|
#4/132
点击查看排名表
|
|
推荐刊物均可到国家新闻出
版总署网站查询正刊
可签署保密协议 ,不透露任
何用户信息可跟踪进程,全程
协议
1对1服务,7x24小时在线
15年经验沉淀,实体公司
运营
liting7111
研究方向:肿瘤 癌症
审稿时间: 2个月内
liting7111
研究方向:肿瘤 癌症
liting7111
研究方向:肿瘤 癌症
审稿时间: 2个月内 接受率: 中等(50%命中)
liting7111
liting7111
研究方向:meta
审稿时间: 2个月内 接受率: 比较困难(25%命中)
liting7111
审稿时间: 2个月内 接受率: 中等(50%命中)
影响因子:2.995
ISSN:0028-3940
研究方向:医学-核医学
影响因子:2.324
ISSN:1051-2284
研究方向:医学-核医学
影响因子:3.156
ISSN:1869-1439
研究方向:CLINICAL NEUROLOGY-RADIOLOGY, NUCLEAR MEDICINE & M
影响因子:4.6
ISSN:0150-9861
研究方向:医学-核医学
影响因子:1.764
ISSN:1591-0199
研究方向:CLINICAL NEUROLOGY-RADIOLOGY, NUCLEAR MEDICINE & M
影响因子:4.966
ISSN:0195-6108
研究方向:医学-核医学
影响因子:3.005
ISSN:0301-0449
研究方向:医学-核医学
影响因子:2.396
ISSN:1793-5458
研究方向:OPTICS-RADIOLOGY, NUCLEAR MEDICINE & MEDICAL IMAGI
影响因子:3.632
ISSN:1084-9785
研究方向:医学-核医学
发表一篇学和医学成像类SCI论文
需要多少钱?
专注医学期刊服务15年
您好:请问您咨询什么等级的期刊?专注医学类期刊发表15年口碑企业,为您提供以下服务:
1.医学核心期刊发表-全流程服务
2.医学SCI期刊-全流程服务
3.论文投稿服务-快速报价
4.期刊推荐直至录用,不成功不收费
客服正在输入...
Clinical & Translational Oncology 投稿经验
(由下方点评分析获得,6人参与,33723人阅读)